Documente Academic
Documente Profesional
Documente Cultură
Erythematous
Maintenance Therapy RS TR
AZA (1-2mg/kg/day) or MMF (1-2
gr/day) Maintenance Therapy Needed Rituximab
+ CYC iv (0,5-0,75 gr/m2/3 Calcineurin Inhibitor
KS (lowered until 0,125 mg/kg/2 days months for one year) IVIg
dose)
MANAGEMENT
General practitioner
PRIMARY HEALTHCARE CENTRE SUSPECTED SLE
Reconcile
3. ANA serology
4. Anti-dsDNA
5. Complement (C3,C4)
PROGNOSIS
• Over the past decade in US, the five-year survival rate
of patients with SLE has improved to more than 95%
because of more effective recognition and treatment of
infectious and renal complication.